Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Cancer Cell

Volumn 20, Issue 1, 2011, Pages 53-65

  Daigle, Scott R ^a   Olhava, Edward J ^a   Therkelsen, Carly A ^a   Majer, Christina R ^a   Sneeringer, Christopher J ^a   Song, Jeffrey ^a   Johnston, L Danielle ^a   Scott, Margaret Porter ^a   Smith, Jesse J ^a   Xiao, Yonghong ^b   Jin, Lei ^a   Kuntz, Kevin W ^a   Chesworth, Richard ^a   Moyer, Mikel P ^a   Bernt, Kathrin M ^b   Tseng, Jen Chieh ^b   Kung, Andrew L ^b   Armstrong, Scott A ^b,c   Copeland, Robert A ^a   Richon, Victoria M ^a   Pollock, Roy M ^a   more..

^a EPIZYME INC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOT1L ENZYME; EPZ 004777; HISTONE METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL KILLING; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GENE TRANSLOCATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MIXED LINEAGE LEUKEMIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 79960058024     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.06.009     Document Type: Article

References (45)

1. Armstrong S.A., Staunton J.E., Silverman L.B., Pieters R., den Boer M.L., Minden M.D., Sallan S.E., Lander E.S., Golub T.R., Korsmeyer S.J. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 2002, 30:41-47.
2. Armstrong S.A., Kung A.L., Mabon M.E., Silverman L.B., Stam R.W., Den Boer M.L., Pieters R., Kersey J.H., Sallan S.E., Fletcher J.A., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003, 3:173-183.
3. Ayton P.M., Cleary M.L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003, 17:2298-2307.
4. Ayton P.M., Chen E.H., Cleary M.L. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol. Cell. Biol. 2004, 24:10470-10478.
5. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78. this issue.
6. Bitoun E., Oliver P.L., Davies K.E. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum. Mol. Genet. 2007, 16:92-106.
7. Chang M.-J., Wu H., Achille N.J., Reisenauer M.R., Chou C.-W., Zeleznik-Le N.J., Hemenway C.S., Zhang W. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010, 70:10234-10242.
8. Copeland R.A. Mechanistic considerations in high-throughput screening. Anal. Biochem. 2003, 320:1-12.
9. Copeland R.A. Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists 2005, Wiley, Hoboken, NJ.
10. Faber J., Krivtsov A.V., Stubbs M.C., Wright R., Davis T.N., van den Heuvel-Eibrink M., Zwaan C.M., Kung A.L., Armstrong S.A. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009, 113:2375-2385.
11. Fang J., Wang H., Zhang Y. Purification of histone methyltransferases from HeLa cells. Methods Enzymol. 2004, 377:213-226.
12. Feng Q., Wang H., Ng H.H., Erdjument-Bromage H., Tempst P., Struhl K., Zhang Y. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr. Biol. 2002, 12:1052-1058.
13. Ferrando A.A., Armstrong S.A., Neuberg D.S., Sallan S.E., Silverman L.B., Korsmeyer S.J., Look A.T. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003, 102:262-268.
14. Guenther M.G., Lawton L.N., Rozovskaia T., Frampton G.M., Levine S.S., Volkert T.L., Croce C.M., Nakamura T., Canaani E., Young R.A. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008, 22:3403-3408.
15. Hess J.L. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 2004, 10:500-507.
16. Jo S.Y., Granowicz E.M., Maillard I., Thomas D., Hess J.L. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011, 117:4759-4768.
17. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7:823-833.
18. Krivtsov A.V., Feng Z., Lemieux M.E., Faber J., Vempati S., Sinha A.U., Xia X., Jesneck J., Bracken A.P., Silverman L.B., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
19. Kumar A.R., Li Q., Hudson W.A., Chen W., Sam T., Yao Q., Lund E.A., Wu B., Kowal B.J., Kersey J.H. A role for MEIS1 in MLL-fusion gene leukemia. Blood 2009, 113:1756-1758.
20. Lin C., Smith E.R., Takahashi H., Lai K.C., Martin-Brown S., Florens L., Washburn M.P., Conaway J.W., Conaway R.C., Shilatifard A. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 2010, 37:429-437.
21. Milne T.A., Briggs S.D., Brock H.W., Martin M.E., Gibbs D., Allis C.D., Hess J.L. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol. Cell 2002, 10:1107-1117.
22. Milne T.A., Martin M.E., Brock H.W., Slany R.K., Hess J.L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 2005, 65:11367-11374.
23. Mohan M., Herz H.M., Takahashi Y.H., Lin C., Lai K.C., Zhang Y., Washburn M.P., Florens L., Shilatifard A. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 2010, 24:574-589.
24. Monroe S.C., Jo S.Y., Sanders D.S., Basrur V., Elenitoba-Johnson K.S., Slany R.K., Hess J.L. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp. Hematol. 2010, 2010:18.
25. Mueller D., Bach C., Zeisig D., Garcia-Cuellar M.P., Monroe S., Sreekumar A., Zhou R., Nesvizhskii A., Chinnaiyan A., Hess J.L., Slany R.K. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007, 110:4445-4454.
26. Mueller D., García-Cuéllar M.P., Bach C., Buhl S., Maethner E., Slany R.K. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol. 2009, 7:e1000249.
27. Nakamura T., Mori T., Tada S., Krajewski W., Rozovskaia T., Wassell R., Dubois G., Mazo A., Croce C.M., Canaani E. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol. Cell 2002, 10:1119-1128.
28. Nguyen A.T., Taranova O., He J., Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 2011, Published online April28 2011.
29. Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., Su L., Xu G., Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
30. Park G., Gong Z., Chen J., Kim J.E. Characterization of the DOT1L network: implications of diverse roles for DOT1L. Protein J. 2010, 29:213-223.
31. Ross M.E., Zhou X., Song G., Shurtleff S.A., Girtman K., Williams W.K., Liu H.C., Mahfouz R., Raimondi S.C., Lenny N., et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003, 102:2951-2959.
32. Ross M.E., Mahfouz R., Onciu M., Liu H.C., Zhou X., Song G., Shurtleff S.A., Pounds S., Cheng C., Ma J., et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004, 104:3679-3687.
33. Rozovskaia T., Feinstein E., Mor O., Foa R., Blechman J., Nakamura T., Croce C.M., Cimino G., Canaani E. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4: 11) abnormality. Oncogene 2001, 20:874-878.
34. Slany R.K. The molecular biology of mixed lineage leukemia. Haematologica 2009, 94:984-993.
35. Slany R.K., Lavau C., Cleary M.L. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol. Cell. Biol. 1998, 18:122-129.
36. Sneeringer C.J., Scott M.P., Kuntz K.W., Knutson S.K., Pollock R.M., Richon V.M., Copeland R.A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. USA 2010, 107:20980-20985.
37. Steger D.J., Lefterova M.I., Ying L., Stonestrom A.J., Schupp M., Zhuo D., Vakoc A.L., Kim J.E., Chen J., Lazar M.A., et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol. Cell. Biol. 2008, 28:2825-2839.
38. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
39. Thiel A.T., Blessington P., Zou T., Feather D., Wu X., Yan J., Zhang H., Liu Z., Ernst P., Koretzky G.A., Hua X. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 2010, 17:148-159.
40. Wong P., Iwasaki M., Somervaille T.C., So C.W., Cleary M.L. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007, 21:2762-2774.
41. Yeoh E.J., Ross M.E., Shurtleff S.A., Williams W.K., Patel D., Mahfouz R., Behm F.G., Raimondi S.C., Relling M.V., Patel A., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
42. Yokoyama A., Lin M., Naresh A., Kitabayashi I., Cleary M.L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010, 17:198-212.
43. Zeisig B.B., Milne T., García-Cuéllar M.P., Schreiner S., Martin M.E., Fuchs U., Borkhardt A., Chanda S.K., Walker J., Soden R., et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol. Cell. Biol. 2004, 24:617-628.
44. Zeleznik-Le N.J., Harden A.M., Rowley J.D. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc. Natl. Acad. Sci. USA 1994, 91:10610-10614.
45. Zhang W., Xia X., Reisenauer M.R., Hemenway C.S., Kone B.C. Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner. J. Biol. Chem. 2006, 281:18059-18068.